Statie Răzvan-Cristian, Florescu Dan Nicolae, Gheonea Dan-Ionuţ, Ciurea Tudorel
Gastroenterology Department, University of Medicine and Pharmacy of Craiova, Romania.
Curr Health Sci J. 2021 Jan-Mar;47(1):132-138. doi: 10.12865/CHSJ.47.01.22. Epub 2021 Mar 31.
Crohn's disease represents an inflammatory bowel disease of unknown etiology, with chronic evolution, which may affect any segment of the digestive tract. The main classes of drugs used in patients with inflammatory bowel disease include: aminosalicylates, corticosteroids, immunosuppressants, biological agents and antibiotics. Biological therapy with anti-TNF-α agents offers significant therapeutic benefits, but their use requires caution, as they can also be associated with numerous side effects. We present the case of a female patient known with Crohn's disease, under going biological therapy with adalimumab, who developed a complication, quite rarely described in the literature, possibly as a result of treatment with anti-TNF-α agents.
克罗恩病是一种病因不明的炎症性肠病，病程呈慢性，可累及消化道的任何节段。用于炎症性肠病患者的主要药物类别包括：氨基水杨酸类、皮质类固醇、免疫抑制剂、生物制剂和抗生素。使用抗TNF-α制剂进行生物治疗可带来显著的治疗益处，但使用时需谨慎，因为它们也可能伴有众多副作用。我们报告一例已知患有克罗恩病的女性患者，正在接受阿达木单抗生物治疗，该患者出现了一种文献中很少描述的并发症，可能是抗TNF-α制剂治疗的结果。
